The Department of Neurology at Jefferson Hospital for Neuroscience has been awarded a multi-million dollar grant from the National Institutes of Health (NIH) for the creation of a center of excellence to study autoimmune diseases from basic science research to its translation into clinical applications. The five-year grant initially totals over $4 million, but could [...]

Aradigm Corporation (OTCBB:ARDM) (the “Company”) announced that the first patient was dosed in a 6-month, multicenter, international Phase 2 clinical trial of a novel version of inhaled ciprofloxacin (ARD-3150) in 40 adult patients with non-cystic fibrosis bronchiectasis.

An experimental drug, LX211 (LUVENIQ™; oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use. Results of international Phase 2/3 clinical trials conducted by Lux Biosciences, to be the subject [...]

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short [...]

European Respiratory Society Congress 2009, Vienna, Austria, 15 September 2009: Symbicort® (budesonide/formoterol) Turbuhaler® Maintenance and Reliever Therapy (Symbicort SMART®) provides effective symptom control and reduces the risk of severe exacerbations in symptomatic asthma patients on inhaled corticosteroids (ICS) or combination therapy of ICS and long-acting beta agonists (LABAs) over six months according to today’s results [...]